Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster ...

The FDA has granted approval to subcutaneous Keytruda for use in adults and pediatric patients with a solid tumor.

The FDA has approved the biologics license application (BLA) for the subcutaneous (SC) administration of pembrolizumab ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

Korean biotech company GI Innovation said Monday it has received Fast Track Designation from the US Food and Drug ...

With a fresh endorsement from the FDA, Johnson & Johnson has rounded out Tremfya’s presence in inflammatory bowel disease ...

The latest findings reported by Novartis reinforce Kesimpta’s efficacy in reducing annualised relapse rate (ARR). The ARTIOS ...

Medical experts have warned against a new weight-loss drug - dubbed the Godzilla of fat-jabs - as it appears to be being sold ...

Merck receives two positive EU CHMP opinions for Keytruda for SC administration and for new indication for earlier-stage head and neck cancer: Rahway, New Jersey Saturday, Septemb ...

Merck & Co. Inc. (NYSE:MRK) is one of the best value stocks in Goldman Sachs’ portfolio. On September 19, the company ...

The drug, which is known as the ‘Godzilla’ of slimming jabs, is still going through lengthy clinical trials in the United ...

Study will evaluate ELI-002 7P in combination with chemotherapy and a checkpoint inhibitor (“CPI”) in the neoadjuvant settingTrial is anticipated ...